thanks for that Thor2Dcore - just reading their presentation so...

thanks for that Thor2Dcore - just reading their presentation so a lot is happening behind the scenes and some near term catalysts as you have pointed out !
Charts look great and i would expect this to run soon back to around 5.8c however we need some news on progress !!

IMP321 clinical development
• Chemoimmunotherapy Phase IIb trial in metastatic breast cancer
→ Approx. 200 patients IMP321 with paclitaxel vs. paclitaxel and placebo
→ Scientific advice from EMA received → Plan to start Q4 2015
• Phase I in immuno-oncology combination → Planning phase of exciting combination study
8
IMP321: AIPAC Study Design

• Multicenter,randomized,doubleblind,PhaseIIb study
• Up to 200 patients with metastatic breast cancer
• Treatment:firstlinepaclitaxel+IMP321/placebo
• Primaryobjective:efficacy(asProgression-Free
  Survival)
• Initiationafteropen-label,safetyrun-inphase:safety
  & evaluation of recommended Phase II dose
• Primarygeographicalfocus:Europe

9
IMP321: Potential Immuno-oncology combination Study Design

• Multicenter, open label, dose escalation, Phase I study
• Planning up to 30 patients with unresectable or metastatic cancer indication with dose escalation
• Treatment: Checkpoint inhibitor + IMP321
• Primary objective: safety, tolerability
• Primary geographical focus: Australia or U

IMP731 for autoimmune diseases

• Dec. 2010. GlaxoSmithKline licensed from Immutep, rights to develop LAG-3 depleting antibodies for autoimmune disease - ₤64m total deal package (~A$118m) + royalties
• GSK2831781 is currently in first time in human clinical trials (see NCT02195349 at clinicaltrials.gov)
• In January 2015, Prima announced a single-digit million dollar milestone for the commencement of GSK’s Phase I study
• GSK’s investigational product aims to kill the few activated LAG-3+ T cells that are auto-reactive in autoimmune disease leading to long term disease control
• Phase I: ongoing

IMP701 is partnered with Novartis
• IMP701 is an anti-LAG-3 antibody which blocks LAG-3-mediated immune down- regulation
• 2012: US biotech CoStim licensed LAG-3 antagonists for cancer from Immutep
• Feb. 2014: Novartis bought CoStim for undisclosed sum
• Phase I expected to start soon
11
CVac update
• CAN-003
– Clear target patient population: in 2nd remission
(CR2) of ovarian cancer
Cancer Tumour-free: Cancer Cancer Tumour-free: treatment 1st Remission recurrence treatment 2nd Remission
– Overall Survival Data with positive trend in CR2: >16 months benefit:42Mo CVac vs 25.53Mo OSC
– Progression free survival data:
>8 months benefit: 12.91Mo for CVac versus PFS=4.94Mo for OSC
– Favorable safety data